By Mill Chart
Last update: May 6, 2024
Uncover the hidden value in MERCK & CO. INC. (NYSE:MRK) as our stock screening tool recommends it as an undervalued choice. NYSE:MRK maintains a robust financial position and offers an attractive pricing perspective. Let's dig deeper into the analysis.
ChartMill assigns a Valuation Rating to each stock, ranging from 0 to 10. This rating is calculated by analyzing different valuation elements, such as price to earnings and free cash flow, both in absolute terms and relative to the market and industry. In the case of NYSE:MRK, the assigned 7 reflects its valuation:
ChartMill employs its own Profitability Rating system for stock evaluation. This score, ranging from 0 to 10, is derived from an analysis of diverse profitability metrics and margins. In the case of NYSE:MRK, the assigned 7 is noteworthy for profitability:
Every stock is evaluated by ChartMill, receiving a Health Rating on a scale of 0 to 10. This assessment considers different health aspects, including liquidity and solvency, both in absolute terms and relative to industry peers. NYSE:MRK has achieved a 5 out of 10:
ChartMill assigns a proprietary Growth Rating to each stock. The score is computed by evaluating various growth aspects, like EPS and revenue growth. We take into account the history as well as the estimated future numbers. NYSE:MRK was assigned a score of 4 for growth:
Every day, new Decent Value stocks can be found on ChartMill in our Decent Value screener.
Our latest full fundamental report of MRK contains the most current fundamental analsysis.
This is not investing advice! The article highlights some of the observations at the time of writing, but you should always make your own analysis and invest based on your own insights.
MERCK & CO. INC.
NYSE:MRK (5/17/2024, 7:14:28 PM)
After market: 131.19 0 (0%)131.19
+0.31 (+0.24%)
With the market potentially posing some challenges, investors may find comfort in considering these safe haven stocks to buy.
Discover essential insights on biotech stocks to sell in May to navigate market volatility and safeguard your investment portfolio.
These are the undervalued healthcare stocks to buy as they represent companies with steady growth visibility.
Based on good technical signals, MERCK & CO. INC. is potentially setting up for a breakout.
The second wave of the weight loss drug stock boom is underway and investors should heed the signs the market is serving.
/CNW/ - Merck (NYSE: MRK), known as MSD outside the United States and Canada, announced that Health Canada has granted approval of KEYTRUDA® (pembrolizumab),...